Cancer Biopsy Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

"What Is the Forecasted Market Size and Growth Rate for the Cancer Biopsy Market?
The market size for cancer biopsies has seen a significant surge recently. The projected growth is from $25.08 billion in 2024 to $28.52 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. This upward trend in the historical period can be traced back to factors such as heightened awareness around breast cancer liquid biopsy procedures, increased understanding of oncology disorders that are inherited and genetic testing, a rise in the preference for liquid biopsies, and a growing demand for minimally invasive biopsy treatments as well as tissue biopsies.

Expectations suggest a fast-paced expansion within the cancer biopsy market in the forthcoming years. It's projected to reach $47.2 billion in 2029, with a compound annual growth rate (CAGR) of 13.4%. The anticipated growth within this forecast period can be credited to a surge in patient numbers, an increase in the elderly demographic, more people being suspected of possessing breast cancer, and an uptick in overall cancer cases. It is further driven by the rise in diagnosis and biopsy tests, as well as an influx of patients. Key trends for this timeframe include advancements in technology, the use of artificial intelligence, machine learning, the integration of multi-omics, innovative products, and developments in point-of-care biopsy devices.

What Factors Are Propelling the Expansion of the Cancer Biopsy Market?
The mounting incidence of cancer plays a pivotal role in driving the upward trend of the cancer biopsy market. Cancer, a multifaceted collection of diseases, is characterised by the irregular proliferation and spread of cells. This rising incidence can be attributed to a host of factors such as a shift in lifestyles and urbanisation, contamination of the environment, the use of tobacco and alcohol, access to healthcare services, and increased awareness. Cancer biopsies are employed to diagnose and gauge the variety, stage, and extent of cancer by extracting and analysing tissues or cells from an area of concern. For example, data from the National Center for Biotechnology Information, an American intergovernmental organization, shows that there were 1,958,310 new cancer diagnoses and 609,820 cancer-related fatalities in the U.S in January 2023. Factoring in data from the National Library of Medicine, a U.S-based medical library, in May 2021, it is forecasted that the burden of cancer worldwide will rise to 28.4 million cases by 2040, reflecting an increase of 47% since 2020, and will result in a significant number of fatalities. Consequently, this growing incidence of cancer is fuelling the cancer biopsy market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp

Which Businesses Are at the Forefront of Cancer Biopsy Market Development?
Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc

What Are the Latest Innovations in the Cancer Biopsy Market?
Leading organizations in the cancer biopsy market are evolving liquid biopsy technologies for seamless, early detection and tracking of cancer, enhancing patient prognosis, and providing tailor-made treatment regimes. Liquid biopsy is a breakthrough, non-intrusive diagnostic method that identifies and studies genetic data from a blood sample, including circulating tumor DNA (ctDNA), RNA, exosomes, and additional biomarkers. For example, in May 2023, Labcorp, a US firm that specializes in producing cancer biopsies, introduced Labcorp Plasma Focus, a liquid biopsy that emphasizes plasma to identify cancer-related biomarkers. The Plasma Focus test evaluates circulating free DNA (cfDNA) emanated from tumor cells present in the bloodstream and can generate a genomic profile of the patient's tumor, indicating mutations in 33 genes involved in various types of cancer, like non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

How Is the Cancer Biopsy Market Segmented?
The cancer biopsymarket covered in this report is segmented -

1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types
2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications
3) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:
1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies
2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing
3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report

Where Is the Cancer Biopsy Market Growth Most Prominent?
North America was the largest region in the cancer biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Cancer Biopsy Global Market Report?

- Market Size Analysis: Analyze the Cancer Biopsy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cancer Biopsy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cancer Biopsy Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cancer Biopsy Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19355

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.